

# Robin Park

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3834212/publications.pdf>

Version: 2024-02-01

42  
papers

478  
citations

840776

11  
h-index

752698

20  
g-index

42  
all docs

42  
docs citations

42  
times ranked

885  
citing authors

#	ARTICLE	IF	CITATIONS
1	The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials. <i>Journal of Hematology and Oncology</i> , 2021, 14, 13.	17.0	49
2	Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer. <i>Anticancer Research</i> , 2018, 38, 5569-5580.	1.1	42
3	Association between the three functional miR-146a single-nucleotide polymorphisms, rs2910164, rs57095329, and rs2431697, and autoimmune disease susceptibility: A meta-analysis. <i>Autoimmunity</i> , 2016, 49, 451-458.	2.6	40
4	Association of active oncologic treatment and risk of death in cancer patients with COVID-19: a systematic review and meta-analysis of patient data. <i>Acta Oncologica</i> , 2021, 60, 13-19.	1.8	36
5	Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 258.	2.8	35
6	Sex-bias in COVID-19-associated illness severity and mortality in cancer patients: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2020, 26, 100519.	7.1	32
7	Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis. <i>Clinical and Translational Oncology</i> , 2021, 23, 100-109.	2.4	30
8	Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma. <i>Clinical Colorectal Cancer</i> , 2019, 18, 81-90.	2.3	25
9	The Role of Aryl-Hydrocarbon Receptor (AhR) in Osteoclast Differentiation and Function. <i>Cells</i> , 2020, 9, 2294.	4.1	19
10	Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma. <i>Vaccines</i> , 2020, 8, 447.	4.4	19
11	Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-Augmented Clinical Trials. <i>Current Colorectal Cancer Reports</i> , 2020, 16, 81-88.	0.5	14
12	Cabozantinib (cabo) combined with durvalumab (durva) in gastroesophageal (GE) cancer and other gastrointestinal (GI) malignancies: Preliminary phase Ib CAMILLA study results.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4563-4563.	1.6	13
13	Outcomes following immunotherapy re-challenge after immune-related adverse event: systematic review and meta-analysis. <i>Immunotherapy</i> , 2020, 12, 1183-1193.	2.0	12
14	Unique gene expression profile in osteoarthritis synovium compared with cartilage: analysis of publicly accessible microarray datasets. <i>Rheumatology International</i> , 2016, 36, 819-827.	3.0	11
15	Comparative Efficacy and Safety of Programmed Death-1 Pathway Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Network Meta-Analysis of Phase III Clinical Trials. <i>Cancers</i> , 2021, 13, 2614.	3.7	11
16	GSK-3Î² in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties. <i>Biology</i> , 2021, 10, 610.	2.8	11
17	Cyclosporine A Treatment Inhibits Abcc6-Dependent Cardiac Necrosis and Calcification following Cxsackievirus B3 Infection in Mice. <i>PLoS ONE</i> , 2015, 10, e0138222.	2.5	10
18	Gene Expression Profile in Patients with Axial Spondyloarthritis: Meta-analysis of Publicly Accessible Microarray Datasets. <i>Journal of Rheumatic Diseases</i> , 2016, 23, 363.	1.1	8

#	ARTICLE	IF	CITATIONS
19	Fulminant COVID-19-Associated Myocarditis in an Otherwise Healthy Female. <i>Cureus</i> , 2021, 13, e12736.	0.5	6
20	Calcium channels: the potential therapeutic targets for inflammatory bone destruction of rheumatoid arthritis. <i>Inflammation Research</i> , 2016, 65, 347-354.	4.0	5
21	Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review. <i>Journal of Pancreatic Cancer</i> , 2020, 6, 107-115.	0.9	5
22	Cutaneous Paraneoplastic Syndrome Associated with Anal Squamous Cell Carcinoma: A Rare Presentation of an Uncommon Cancer. <i>Current Oncology</i> , 2020, 27, 433-435.	2.2	4
23	Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2682.	2.4	4
24	Association Between the Functional <i>miR-146a</i> SNP <i>rs2910164</i> and Risk of Digestive System Cancer: Updated Meta-analysis. <i>Anticancer Research</i> , 2020, 40, 1495-1502.	1.1	4
25	Impact of BRAF mutations on prognosis and immunotherapy response in microsatellite instability/mismatch repair deficient metastatic colorectal cancer: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3557-3557.	1.6	4
26	The prognostic and predictive impact of <i>BRAF</i> mutations in deficient mismatch repair/microsatellite instability-high colorectal cancer: systematic review/meta-analysis. <i>Future Oncology</i> , 2021, 17, 4221-4231.	2.4	4
27	Is obesity a risk factor in cancer patients with COVID-19?. <i>Future Oncology</i> , 2021, 17, 3541-3544.	2.4	4
28	Complete Resolution of a Large, Locally-advanced Cutaneous Squamous Cell Carcinoma with the Immune-modulating PD-1 Inhibitor Pembrolizumab. <i>Cureus</i> , 2020, 12, e8072.	0.5	4
29	345â€¦Phase I/II trial of cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies (CAMILLA): phase Ib safety and efficacy results. , 2021, 9, A372-A372.		4
30	Exceptional response to neoadjuvant capecitabine and temozolomide in TSC2-mutant pancreatic neuroendocrine tumor. <i>Current Problems in Cancer Case Reports</i> , 2020, 2, 100037.	0.1	3
31	Prognostic impact of obesity in cancer patients with COVID-19 infection: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18578-e18578.	1.6	3
32	The Role of Bile Acid Receptors in Chronic Inflammatory Diseases. <i>Journal of Rheumatic Diseases</i> , 2017, 24, 253.	1.1	2
33	Coinfection of <i>Helicobacter pylori</i> and Hepatitis C Virus in the Development of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine Research</i> , 2021, 13, 530-540.	1.2	2
34	Comparison of systemic therapy efficacy in advanced hepatocellular carcinoma: Systematic review and frequentist network meta-analysis of randomized controlled trials.. <i>Journal of Clinical Oncology</i> , 2021, 39, 293-293.	1.6	1
35	Current landscape of immunotherapy trials in locally advanced and high-risk head and neck cancer. <i>Immunotherapy</i> , 2021, 13, 931-940.	2.0	1
36	Treatment-related adverse events of combination immune checkpoint inhibitors: Systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15060-e15060.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Pathologically Complete Response after Triple Therapy in Locally Advanced Esophageal Cancer in a Hereditary Hemorrhagic Telangiectasia Patient. <i>Case Reports in Oncology</i> , 2020, 13, 176-181.	0.7	0
38	Efficacy and safety of PD-1 inhibitors as first- and second- line treatments for advanced gastroesophageal cancers: A network meta-analysis of phase III clinical trials.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16032-e16032.	1.6	0
39	Internal medicine residentsâ€™ awareness on cancer survivorship care plan: A cross sectional study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e23011-e23011.	1.6	0
40	Checkpoint inhibitor-associated immune-related adverse events as harbinger of favorable clinical outcome: Systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15129-e15129.	1.6	0
41	Temozolomide treatment duration and secondary hematological neoplasms: A review of the literature and implications for patients with neuroendocrine tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 510-510.	1.6	0
42	CA209-8YD: A phase I/II trial of rucaparib in combination with ramucirumab with or without nivolumab in previously treated advanced gastroesophageal adenocarcinoma (GEA) (RiME).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS377-TPS377.	1.6	0